WO2006110881A3 - Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins - Google Patents

Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins Download PDF

Info

Publication number
WO2006110881A3
WO2006110881A3 PCT/US2006/013905 US2006013905W WO2006110881A3 WO 2006110881 A3 WO2006110881 A3 WO 2006110881A3 US 2006013905 W US2006013905 W US 2006013905W WO 2006110881 A3 WO2006110881 A3 WO 2006110881A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
yersinia
immunomodulatory proteins
polypeptide vaccines
ifn
Prior art date
Application number
PCT/US2006/013905
Other languages
French (fr)
Other versions
WO2006110881A2 (en
Inventor
Robert R Brubaker
Vyacheslav M Abrabov
Original Assignee
Univ Michigan State
Robert R Brubaker
Vyacheslav M Abrabov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan State, Robert R Brubaker, Vyacheslav M Abrabov filed Critical Univ Michigan State
Publication of WO2006110881A2 publication Critical patent/WO2006110881A2/en
Publication of WO2006110881A3 publication Critical patent/WO2006110881A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed are compositions, including LcrV antigenic polypeptides, vaccines and antibodies, as well as associated methods for treating and/or preventing Yersinia infection in a host. The invention further provides immunomodulatory LcrV proteins and polypeptides comprising TLR2 and IFN-ϜR-IFN-Ϝ -binding sequences that stimulate host anti-inflammatory responses and repress pro-inflammatory responses.
PCT/US2006/013905 2005-04-12 2006-04-12 Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins WO2006110881A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67077105P 2005-04-12 2005-04-12
US60/670,771 2005-04-12

Publications (2)

Publication Number Publication Date
WO2006110881A2 WO2006110881A2 (en) 2006-10-19
WO2006110881A3 true WO2006110881A3 (en) 2007-03-29

Family

ID=37087696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013905 WO2006110881A2 (en) 2005-04-12 2006-04-12 Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins

Country Status (1)

Country Link
WO (1) WO2006110881A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
WO2013059299A1 (en) * 2011-10-17 2013-04-25 The Uab Research Foundation Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
WO2016193161A1 (en) 2015-05-29 2016-12-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multivalent immunogenic composition for inducing an immune response against yersinia species

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024475A1 (en) * 1994-03-08 1995-09-14 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccine compositions
WO2005023205A2 (en) * 2003-03-07 2005-03-17 University Of Massachusetts Compositions and methods for yersinia pestis treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024475A1 (en) * 1994-03-08 1995-09-14 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccine compositions
WO2005023205A2 (en) * 2003-03-07 2005-03-17 University Of Massachusetts Compositions and methods for yersinia pestis treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAKAJIMA R ET AL: "ASSOCATION BETWEEN VIRULENCE OF YERSINIA PESTIS AND SUPPRESSION OF GAMMA INTERFERON AND TUMOR NECROSIS FACTOR ALPHA", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 61, no. 1, January 1993 (1993-01-01), pages 23 - 31, XP008052043, ISSN: 0019-9567 *
PULLEN JEFFREY K ET AL: "Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes", INFECTION AND IMMUNITY, vol. 66, no. 2, February 1998 (1998-02-01), pages 521 - 527, XP002410484, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2006110881A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
DK1701968T3 (en) THE IMMUNOGENE PEPTID-CARRIER CONJUGATES AND PROCEDURES FOR THEIR PREPARATION
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2008156655A3 (en) Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
DK1620456T3 (en) HLA-A2 TUMOR-ASSOCIATED ANTIGEN PEPTIDES AND PREPARATIONS
WO2006042149A3 (en) Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
WO2006110728A3 (en) Immunogenic cmv tegument aggregates
WO2004069184A3 (en) Methods for treating, preventing and detecting helicobacter infection
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
IS7798A (en) Compounds, pharmaceutical preparations and methods
WO2007050095A3 (en) Improved vaccines and methods for using the same
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
WO2002024739A3 (en) Spas-1 cancer antigen
WO2009020553A3 (en) Chlamydia antigens
MX2009007572A (en) Fusion protein.
WO2004091524A3 (en) Respiratory virus vaccines
WO2006110881A3 (en) Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins
WO2007082105A3 (en) Chlamydia vaccine
EP1703887A4 (en) Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
WO2006073827A3 (en) Neutralizing epitope-based growth enhancing vaccine
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
WO2003093298A3 (en) Immunogenic peptides
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06758327

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06758327

Country of ref document: EP

Kind code of ref document: A2